Page 1

Biogen . BIOGEN REPORTS SECOND QUARTER 2021 RESULTS Second quarter revenue $ 2,775 million ; GAAP diluted EPS $ 2.99 ; Non - GAAP diluted EPS $ 5.68 Received accelerated approval for ADUHELM ( aducanumab - avwa ) in the U.S. for initiation of treatment in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease Received FDA Breakthrough Therapy designation for lecanemab ( BAN2401 ) Advancing a diversified neuroscience pipeline with positive readouts in Phase 3 study in depression and Phase 2a study in stroke ● New collaborations across multiple modalities including potential oral therapy for all forms of multiple sclerosis Cambridge , Mass . , July 22 , 2021 -- Biogen Inc. ( Nasdaq : BIIB ) today reported second quarter 2021 financial results . " We were pleased with our operational performance in the second quarter , " said Michel Vounatsos , Biogen's Chief Executive Officer . " Biogen has the market - leading portfolio of therapies for MS , has launched the first approved and market - leading therapy for SMA , and now has the first approved therapy to address a defining pathology of Alzheimer's disease . In addition , we recently reported positive data in depression and stroke , and we look forward to the expected Phase 3 data for tofersen , the first genetically - targeted potential therapy for ALS , for which we have begun offering individual compassionate use access . " Second Quarter 2021 Financial Results Second quarter total revenue of $ 2,775 million decreased 25 % versus the prior year at actual currency and decreased 26 % at constant currency * . o Multiple sclerosis ( MS ) revenue , including royalties on sales of OCREVUS® , of $ 1,786 million decreased 24 % versus the prior year at both actual and constant currency . SPINRAZAⓇ revenue of $ 500 million increased 1 % versus the prior year at actual currency and decreased 3 % at constant currency . O ADUHELM ™ revenue was $ 2 million . O Biosimilars revenue of $ 202 million increased 18 % versus the prior year at actual currency and increased 9 % at constant currency .